Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Multi-level Segmentation Solution

    September 6, 2017 | Case study, Quantitative, Segmentation 

    Our client has an established product for multiple indications. They wanted to create a HCP segmentation typing tool which could be implemented in-field to help classify physicians across two different therapeutic areas. There was rationale to suggest that because the two therapeutic areas are pathologically different, then two separate typing tools would be required. However, it was also argued that a one segment solution would be most suitable as physicians fundamentally have the same attitudes, irrespective of the disease they are treating. Additionally, our client would be able to implement a single segmentation tool into its core business much more efficiently than two separate tools. The challenge was to therefore decide whether a one tool or two tool solution would be most suitable.

    Find out more: https://www.researchpartnership.com/news/2017/08/multi-level-segmentation-solution/

    This content was provided by Inizio

    Company Details

    - PMLiVE

    Inizio

    Email
    Website

     Latest Content from  Inizio 

    Inizio Engage CEO Jim Sage featured in pharmaphorum’s “12 Questions” series

    Discover Jim Sage’s insights on leadership, industry challenges, and the transformative impact of data, technology, and patient-centric innovation in his latest pharmaphorum “12 Questions” interview.

    Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025

    As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...

    How DataGateway unified oncology data for real-world insights & market intelligence

    Discover how our DataGateway platform unifies fragmented real-world oncology data into a single, validated dataset that delivers deeper insights and faster decision-making.

    Inizio launches InConcert™ to transform pre-launch planning through connected intelligence.

    Inizio today announced the launch of InConcert™, a new AI-powered data solution designed to accelerate smarter, evidence-led decisions during the critical pre-launch phase of the product lifecycle.

    ESMO 2025 highlights: How storytelling, design & emotion are transforming scientific engagement

    Discover key insights from ESMO 2025 on how design, emotion, and sustainability are reshaping medical congress experiences. Featuring expert takes from Inizio leaders.

    Preparing for ASH 2025: Pharma’s role in hematology innovation

    As the global hematology community prepares for the 67th ASH® Annual Meeting and Exposition, Inizio experts share their perspectives on what’s driving the field forward – and how pharma companies...

    AI without limits: A smarter, integrated approach to Medical Affairs

    At Inizio Medical, we believe AI isn’t replacing Medical Affairs — it’s redefining what’s possible. Our platform, iON.AI™, enhances human expertise, streamlines complex workflows, and strengthens strategic impact through seamless...

    What to expect from Obesity Week 2025: Key trends shaping the future of obesity care

    Discover how Inizio experts are shaping the future of obesity care—where science, strategy, and innovation unite to advance cardiometabolic health and drive real-world impact.

    AI with intent: How Inizio is redefining pharma through precision and partnership

    At Fierce Pharma Week, Inizio revealed how the fusion of human expertise and purposeful AI is reshaping pharma communications and driving real-world impact—discover how this human-centered innovation is defining the...

    Leading the future of Intelligent Commercialization™: Where proprietary data, tech, and AI meet expert insight

    Inizio is leading the way in Intelligent Commercialization™ by uniting proprietary AI-powered platforms, deep scientific expertise, and proven governance to unlock measurable, lasting value at every stage of commercialization.